Early-stage pharma developer Sareum Holdings (AIM:SAR) is making good progress on its pipeline of projects, justifying the share price rise increases earlier this year.
With Covid spreading damage particularly hard in the UK in the early months of 2021 shares rocketed to 8.85 pence in August – from 220 pence at the end of 2020 – as investors' focus zeroed in on the company’s research on a molecule that could be used to treat breathing complications caused by the virus.
The rest of this page is for members only. Please log in below or visit the registration page for Armchair Trader+ to see the benefits of becoming a member.
Log In or Sign Up to Armchair Trader+
Already a member? Log in here:
Not a member yet? Sign up for your free trial or check out the benefits of membership.
Further content of this article is not available as it is for members only. Please visit the registration page for Armchair Trader+ for further details on the benefits of becoming a member.